Furthermore, some clinical studies have shown potential contribution of STING signaling in patients with NAFLD by linking the release of mtDNA and the progression inflammation and fibrosis in the liver (92, 95). Here, STING1 is linked to metabolic dysfunction-associated steatotic liver disease.